Prophylactic effect of IL-10 gene transfer on induced autoimmune dacryoadenitis

Investigative Ophthalmology and Visual Science

Volumn 45, Issue 5, 2004, Pages 1375-1381

  Zhu, Zejin ^a   Stevenson, Douglas ^a   Schechter, Joel E ^a   Mircheff, Austin K ^a   Ritter, Thomas ^b   Labree, Laurie ^a   Trousdale, Melvin D ^a,c  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b HUMBOLDT UNIVERSITY   (Germany)

^c DOHENY EYE INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CD18 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; INTERLEUKIN 10; LYMPHOCYTE ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; RABBIT THYMIC LYMPHOCYTE ANTIGEN; UNCLASSIFIED DRUG; HLA ANTIGEN CLASS 2; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ANTIGEN EXPRESSION; ARTICLE; AUTOIMMUNE DISEASE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DACRYOADENITIS; DACRYOCYSTITIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION REGULATION; GENE TRANSFER; IMMUNOPATHOLOGY; IN VIVO STUDY; LACRIMAL GLAND DISEASE; LYMPHOCYTE ACTIVATION; MIXED CELL CULTURE; NONHUMAN; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; QUANTITATIVE DIAGNOSIS; RABBIT; SCORING SYSTEM; SJOEGREN SYNDROME; STATISTICAL SIGNIFICANCE; TEAR FILM; ADENOVIRUS; ANIMAL; CD4+ T LYMPHOCYTE; DISEASE MODEL; ENZYME IMMUNOASSAY; GENE THERAPY; GENE VECTOR; GENETICS; LACRIMAL FLUID; METABOLISM; PATHOLOGY;

ADENOVIRIDAE; ANIMALS; ANTIGENS, CD18; ANTIGENS, CD4; ANTIGENS, CD8; AUTOIMMUNE DISEASES; CD4-POSITIVE T-LYMPHOCYTES; DACRYOCYSTITIS; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HISTOCOMPATIBILITY ANTIGENS CLASS II; IMMUNOENZYME TECHNIQUES; INTERLEUKIN-10; LYMPHOCYTE ACTIVATION; LYMPHOCYTE FUNCTION-ASSOCIATED ANTIGEN-1; RABBITS; SJOGREN'S SYNDROME; TEARS;

EID: 2442706846     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: 10.1167/iovs.03-0755     Document Type: Article

References (45)

1. Talal N. What is Sjögren's syndrome and why is it important? J Rheumatol Suppl. 2000;61:1-3.
2. Fox RI. Sjögren's syndrome. Curr Opin Rheumatol. 1995;7:409-416.
3. Sullivan DA, Wickham LA, Krenzer KL, Rocha EM, Toda I. Aqueous tear deficiency in Sjögren's syndrome: possible causes and potential treatment. In: Pleyer U, Hartmann C, Sterry W, eds. Oculodermal Diseases: Immunology of Bullous Oculo-muco-cutaneous Disorders. Buren, The Netherlands: Aeolus Press; 1997:95-152.
4. Esch TR. Pathogenetic factors in Sjögren's syndrome: recent developments. Crit Rev Oral Biol Med. 2001;12:244-251.
5. Kolkowski EC, Reth P, Pelusa F, et al. Th1 predominance and perforin expression in minor salivary glands from patients with primary Sjögren's syndrome. J Autoimmun. 1999;13:155-162.
6. Sun D, Emmert-Buck MR, Fox PC. Differential cytokine mRNA expression in human labial minor salivary glands in primary Sjögren's syndrome. Autoimmunity. 1998;28:125-137.
7. Magnusson V, Nakken B, Bolstad AI, Alarcon-Riquelme ME. Cytokine polymorphisms in systemic lupus erythematosus and Sjögren's syndrome. Scand J Immunol. 2001;54:55-61.
8. Solomon A, Dursun D, Liu Z, Xie Y, Macri A, Pflugfelder SC. Proand anti-inflammatory forms of interleukin-1 in the tear fluid and conjunctiva of patients with dry eye disease. Invest Ophthalmol Vis Sci. 2001;42:2283-2292.
9. Boumba D, Skopouli FN, Moutsopoulos HM. Cytokine mRNA expression in the labial salivary gland tissues from patients with primary Sjögren's syndrome. Br J Rheumatol. 1995;34:326-333.
10. Mitsias DI, Tzioufas AG, Veiopoulou C, et al. The Th1/Th2 cytokine balance changes with the progress of the immunopathological lesion of Sjögren's syndrome. Clin Exp Immunol. 2002;128:562-568.
11. De Vita S, Dolcetti R, Ferraccioli G, et al. Local cytokine expression in the progression toward B cell malignancy in Sjögren's syndrome. J Rheumatol. 1995;22:1674-1680.
12. Fox RI, Kang HI, Ando D, et al. Cytokine mRNA expression in salivary gland biopsies of Sjögren's syndrome. J Immunol. 1994;152:5532-5539.
13. Fiorentino DF, Bond MW, Mosmann TR. Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J Exp Med. 1989;170:2081-2095.
14. Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol. 2001;19:683-765.
15. Akdis CA, Blaser K. Mechanisms of interleukin-10-mediated immune suppression. Immunology. 2001;103:131-136.
16. Go NF, Castle BE, Barrett R, et al. Interleukin 10, a novel B cell stimulatory factor: unresponsiveness of X chromosome-linked immunodeficiency B cells. J Exp Med. 1990;172:1625-1631.
17. Vieira P, de Waal-Malefyt R, Dang MN, et al. Isolation and expression of human cytokine synthesis inhibitory factor cDNA clones: homology to Epstein-Barr virus open reading frame BCRFI. Proc Natl Acad Sci USA. 1991;88:1172-1176.
18. Jorgensen C, Apparailly F, Sany J. Immunological evaluation of cytokine and anticytokine immunotherapy in vivo: what have we learnt? Ann Rheum Dis. 1999;58:136-141.
19. Asadullah K, Sterry W, Stephanek K, et al. IL10 is a key cytokine in psoriasis: proof of principle by IL-10 therapy-a new therapeutic approach. J Clin Invest. 1998;101:783-794.
20. Zhu Z, Stevenson D, Ritter T, et al. Expression of IL-10 and TNF-inhibitor genes in lacrimal gland epithelial cells suppresses their ability to activate lymphocytes. Cornea. 2002;21:210-214.
21. Zhu Z, Stevenson D, Schechter JE, Mircheff AK, Atkinson R, Trousdale MD. Lacrimal histopathology and ocular surface disease in a rabbit model of autoimmune dacryoadenitis. Cornea. 2003;22:25-32.
22. Pretolani M. Interleukin-10: an anti-inflammatory cytokine with therapeutic potential. Clin Exp Allergy. 1999;29:1164-1171.
23. Mottonen M, Isomaki P, Saario R, Toivanen P, Punnonen J, Lassila O. Interleukin-10 inhibits the capacity of synovial macrophages to function as antigen-presenting cells. Br J Rheumatol. 1998;37:1207-1214.
24. Ferguson TA. The molecular basis of anterior associated immune deviation (ACAID). Ocul Immunol Inflamm. 1997;5:213-215.
25. Balasa B, La Cava A, Van Gunst K, et al. A mechanism for IL-10-mediated diabetes in the nonobese diabetic (NOD) mouse: ICAM-1 deficiency blocks accelerated diabetes. J Immunol. 2000;165:7330-7337.
26. De Kozak Y, Thillaye-Goldenberg B, Naud MC, Da Costa AV, Auriault C, Verwaerde C. Inhibition of experimental autoimmune uveoretinitis by systemic and subconjunctival adenovirus-mediated transfer of the viral IL-10 gene. Clin Exp Immunol. 2002;130:212-223.
27. van Roon JA, Lafeber FP, Bijlsma JW. Synergistic activity of interleukin-4 and interleukin-10 in suppression of inflammation and joint destruction in rheumatoid arthritis. Arthritis Rheum. 2001;44:3-12.
28. Rizzo LV, Xu H, Chan CC, Wiggert B, Caspi RR. IL-10 has a protective role in experimental autoimmune uveoretinitis. Int Immunol. 1998;10:807-814.
29. Apparailly F, Verwaerde C, Jacquet C, Auriault C, Sany J, Jorgensen C. Adenovirus-mediated transfer of viral IL-10 gene inhibits murine collagen-induced arthritis. J Immunol. 1998;160:5213-5220.
30. Ma Y, Thornton S, Duwel LE, et al. Inhibition of collagen-induced arthritis in mice by viral IL-10 gene transfer. J Immunol. 1998;161:1516-1524
31. Kaya Z, Dohmen KM, Wang Y, et al. Cutting edge: a critical role for IL-10 in induction of nasal tolerance in experimental autoimmune myocarditis. J Immunol. 2002;168:1552-1556.
32. Klebe S, Sykes P, Coster D, Krishnan R, Williams K. Prolongation of sheep corneal allograft survival by ex vivo transfer of the gene encoding interleukin-10. Transplantation. 2001;71:1214-1220.
33. Zhu Z, Stevenson D, Schechter JE, et al. Tumor necrosis factor inhibitor gene expression suppresses lacrimal gland immunopathology in a rabbit model of autoimmune dacryoadenitis. Cornea. 2003;22:343-351.
34. Boumba D, Skopouli FN, Moutsopoulos HM. Cytokine mRNA expression in the labial salivary gland tissues from patients with primary Sjögren's syndrome. Br J Rheumatol. 1995;34:326-333.
35. Garcic-Carrasco M, Font J, Filella X, et al. Circulating levels of Th1/Th2 cytokines in patients with primary Sjögren's syndrome: correlation with clinical and immunological features. Clin Exp Rheumatol. 2001;19:411-415.
36. Perrier S, Serre AF, Dubost JJ, et al. Increased serum levels of interleukin 10 in Sjögren's syndrome; correlation with increased IgG1. J Rheumatol. 2000;27:935-939.
37. Yanagi K, Ishimaru N, Haneji N, et al. Anti-120-kDa alpha fodrin immune response with Th1 cytokine profile in the NOD mouse model of Sjögren's syndrome. Eur J Immunol. 1998;28:3336-3345.
38. Mustafa W, Zhu J, Deng G, et al. Augmented levels of macrophage and Th1 cell-related cytokine mRNA in submandibular glands of MRL/1pr mice with autoimmune sialadenitis. Clin Exp Immunol. 1998;112:389-396.
39. Yanagi K, Haneji N, Hamano H, Takahashi M, Higashima H, Hayashi Y. In vivo role of IL-10 and IL-12 during development of Sjögren's syndrome in MRL/1pr mice. Cell Immunol. 1996;168:243-250.
40. Jabs DA, Prendergast RA, Rorer EM. Hudson AP, Whittum-Hudson JA. Cytokines in autoimmune lacrimal gland disease in MRL/mpJ mice. Invest Ophthalmol Vis Sci. 2001;42:2567-2571.
41. Saito I. Structure of IL-10 and its role in autoimmune exocrinopathy. Crit Rev Immunol. 2000;20:153-165.
42. Saito I, Haruta K, Shimuta M, et al. Fas ligand-mediated exocrinopathy resembling Sjögren's syndrome in mice transgenic for IL-10. J Immunol. 1999;162:2488-2494.
43. Ohlsson M, Skarstein K, Blostad AI, et al. Fas-induced apoptosis is a rare event in Sjögren's syndrome. Lab Invest. 2001;81:95-105.
44. Bolstad AI, Eiken JG, Rosenlund B, et al. Increased salivary gland tissue expression of Fas, Fas ligand, cytotoxic lymphocyte-associated antigen-4, and programmed cell death 1 in primary Sjögren's syndrome. Arthritis Rheum. 2003;48:174-185.
45. Mircheff AK, Hamm-Alvarez SF, Kaslow HR, Schechter JE, Trousdale MD. Epithelial cells in lymphocyte regulation in the lacrimal gland. In: Zierhut M, ed. Immunology of the Ocular Surface and the Lacrimal Glands. Amsterdam: Swets & Zeitlinger. In press.